zanamivir has been researched along with Critical Illness in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haringman, JJ; Koch, BC; Ter Horst, PG; Wagenvoort, GH; Wieringa, A | 1 |
| Martin-Loeches, I; O'Sullivan, S; Rodriguez, A; Torres, A | 1 |
| Slain, D | 1 |
| Louie, JK; Samuel, MC; Schechter, R; Uyeki, TM; Yang, S | 1 |
| Härter, G; Kern, P; Maier, L; Mertens, T; Schubert, A; Wöhrle, J; Zimmermann, O | 1 |
| Chappell, JD; Creech, CB; Denison, MR; Domm, J; Dulek, DE; Frangoul, HA; Schulert, AK; Williams, JV | 1 |
| Bellomo, R; Charles, PG; Gordon, CL; Grayson, ML; Hart, GK; Johnson, PD; Langan, K; Torresi, J | 1 |
| Ellermann-Eriksen, S; Gubbels, S; Ilkjær, S; Jensen-Fangel, S; Keld, DB; Lindskov, C; Petersen, E | 1 |
| Al-Hegelan, MS; Cheifetz, IM; Noble, PW; Ozment, CP; Peters, MA; Peterson-Carmichael, SL; Rehder, KJ; Turner, DA; Williford, WL | 1 |
| Beersma, MF; Boucher, CA; de Jong, MD; Fouchier, RA; Fraaij, PL; Horrevorts, AM; Houmes, RJ; Koopmans, MP; Kroes, AC; Niesters, HG; Osterhaus, AD; Reis Miranda, D; Ridwan, BU; Riezebos-Brilman, A; van der Eijk, AA; van der Vries, E; van Dissel, JT; Wolfhagen, MJ | 1 |
1 review(s) available for zanamivir and Critical Illness
| Article | Year |
|---|---|
Influenza management with new therapies.
Topics: Adrenal Cortex Hormones; Amides; Antiviral Agents; Critical Care; Critical Illness; Dibenzothiepins; Enzyme Inhibitors; Humans; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyrazines; Pyridines; Pyridones; Pyrimidines; Pyrroles; Respiration, Artificial; Triazines; Zanamivir | 2020 |
9 other study(ies) available for zanamivir and Critical Illness
| Article | Year |
|---|---|
Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration.
Topics: Continuous Renal Replacement Therapy; Critical Illness; Hemofiltration; Humans; Tandem Mass Spectrometry; Zanamivir | 2023 |
Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza.
Topics: Antiviral Agents; Critical Illness; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2021 |
Neuraminidase inhibitors for critically ill children with influenza.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; California; Child; Child, Preschool; Critical Care; Critical Illness; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pandemics; Population Surveillance; Treatment Outcome; Zanamivir | 2013 |
Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus.
Topics: Adult; Antiviral Agents; Critical Illness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intravenous; Male; Middle Aged; Pneumonia; Respiratory Distress Syndrome; Treatment Outcome; Zanamivir | 2010 |
Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
Topics: Antiviral Agents; Compassionate Use Trials; Critical Illness; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intravenous; Oseltamivir; Treatment Outcome; Viral Load; Zanamivir | 2010 |
Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency.
Topics: Adult; Antiviral Agents; Common Variable Immunodeficiency; Critical Illness; Female; Humans; Immunoglobulin G; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Pneumonia; Pregnancy; Salvage Therapy; Treatment Outcome; Zanamivir | 2011 |
Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Child; Critical Illness; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiration, Artificial; Time Factors; Treatment Failure; Virus Shedding; Zanamivir | 2011 |
Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A.
Topics: Adolescent; Adult; Antiviral Agents; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Oseltamivir; Respiratory Insufficiency; Retrospective Studies; Young Adult; Zanamivir | 2011 |
Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.
Topics: Adolescent; Adult; Child, Preschool; Critical Illness; Drug Therapy, Combination; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Middle Aged; Netherlands; Oseltamivir; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load; Zanamivir | 2011 |